Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kristina Masson

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Cellular Signalling|June 23, 2009
Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3Kristina Masson, Lars Rönnstrand
The Biochemical Journal|June 20, 2006
Direct binding of Cbl to Tyr568 and Tyr936 of the stem cell factor receptor/c-Kit is required for ligand-induced ubiquitination, internalization and degradationKristina Masson, Elke Heiss, Hamid Band, et al.
British Journal of Haematology|May 15, 2009
A role of Gab2 association in Flt3 ITD mediated Stat5 phosphorylation and cell survivalKristina Masson, Tao Liu, Rasheed Khan, et al.
Experimental Hematology|May 30, 2009
Oncogenic Flt3 receptors display different specificity and kinetics of autophosphorylationElena Razumovskaya, Kristina Masson, Rasheed Khan, et al.
Blood|May 11, 2006
Identification of Y589 and Y599 in the juxtamembrane domain of Flt3 as ligand-induced autophosphorylation sites involved in binding of Src family kinases and the protein tyrosine phosphatase SHP2Elke Heiss, Kristina Masson, Christina Sundberg, et al.
Blood|January 16, 2009
A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AMLFrank Breitenbuecher, Boyka Markova, Stefan Kasper, et al.
NPJ Systems Biology and Applications|September 26, 2017
Predicting ligand-dependent tumors from multi-dimensional signaling featuresHelge Hass, Kristina Masson, Sibylle Wohlgemuth, et al.
The Journal of Biological Chemistry|January 26, 2011
Protein-tyrosine phosphatase DEP-1 controls receptor tyrosine kinase FLT3 signalingDeepika Arora, Sabine Stopp, Sylvia-Annette Böhmer, et al.
ACS Medicinal Chemistry Letters|December 21, 2012
A Potent and Selective Quinoxalinone-Based STK33 Inhibitor Does Not Show Synthetic Lethality in KRAS-Dependent CellsMichel Weïwer, James Spoonamore, Jingqiang Wei, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 11, 2012
STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viabilityTuoping Luo, Kristina Masson, Jacob D Jaffe, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Cellular Signalling|June 23, 2009
Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3Kristina Masson, Lars Rönnstrand
The Biochemical Journal|June 20, 2006
Direct binding of Cbl to Tyr568 and Tyr936 of the stem cell factor receptor/c-Kit is required for ligand-induced ubiquitination, internalization and degradationKristina Masson, Elke Heiss, Hamid Band, et al.
British Journal of Haematology|May 15, 2009
A role of Gab2 association in Flt3 ITD mediated Stat5 phosphorylation and cell survivalKristina Masson, Tao Liu, Rasheed Khan, et al.
Experimental Hematology|May 30, 2009
Oncogenic Flt3 receptors display different specificity and kinetics of autophosphorylationElena Razumovskaya, Kristina Masson, Rasheed Khan, et al.
Blood|May 11, 2006
Identification of Y589 and Y599 in the juxtamembrane domain of Flt3 as ligand-induced autophosphorylation sites involved in binding of Src family kinases and the protein tyrosine phosphatase SHP2Elke Heiss, Kristina Masson, Christina Sundberg, et al.
Blood|January 16, 2009
A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AMLFrank Breitenbuecher, Boyka Markova, Stefan Kasper, et al.
NPJ Systems Biology and Applications|September 26, 2017
Predicting ligand-dependent tumors from multi-dimensional signaling featuresHelge Hass, Kristina Masson, Sibylle Wohlgemuth, et al.
The Journal of Biological Chemistry|January 26, 2011
Protein-tyrosine phosphatase DEP-1 controls receptor tyrosine kinase FLT3 signalingDeepika Arora, Sabine Stopp, Sylvia-Annette Böhmer, et al.
ACS Medicinal Chemistry Letters|December 21, 2012
A Potent and Selective Quinoxalinone-Based STK33 Inhibitor Does Not Show Synthetic Lethality in KRAS-Dependent CellsMichel Weïwer, James Spoonamore, Jingqiang Wei, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 11, 2012
STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viabilityTuoping Luo, Kristina Masson, Jacob D Jaffe, et al.
Pageof 2